SCHEMBL216428

SCHEMBL216428

NC(=O)c1c(C(=O)Nc2ccc(OCCCN3CCNCC3)cc2C(F)(F)F)ncn1-c1nc2ccccc2[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 5/20 0.38
ITGA2B P08514 5/20 0.38
AVPR1B P47901 1/20 0.38
SIRT1 Q96EB6 1/20 0.37
HRH3 Q9Y5N1 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
LTA4H P09960 1/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
DRD3 P35462 3/20 0.36
ULK1 O75385 1/20 0.36
CHEK2 O96017 1/20 0.35
PARP1 P09874 1/20 0.35
DRD2 P14416 2/20 0.35
TRPV4 Q9HBA0 1/20 0.34
BACE1 P56817 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL214532 0.99 ITGB3 (0.39) ITGB3ITGA2BAVPR1BSIRT1HRH3
SCHEMBL216182 0.84 DRD3 (0.41) ITGB3ITGA2BAVPR1BSIRT1MAPT
Hydrochloric Acid SCHEMBL215262 0.84 ITGB3 (0.41) ITGB3ITGA2BAVPR1BSIRT1LTA4H
SCHEMBL214316 0.83 BTK (0.42) AVPR1BLTA4H
SCHEMBL216885 0.80 CNR1 (0.42) SMN1; SMN2PARP1
SCHEMBL214093 0.80 DRD3 (0.40) HRH3MEN1MAPTKMT2ASMN1; SMN2
SCHEMBL2735363 0.80 NPC1 (0.40) ITGB3ITGA2BAVPR1BSIRT1HRH3
SCHEMBL215285 0.79 LTA4H (0.46) ALDH1A1SMN1; SMN2LTA4HDRD3DRD2
SCHEMBL213323 0.79 LTA4H (0.46) ALDH1A1LTA4H
SCHEMBL214644 0.77 MEN1 (0.39) ITGB3ITGA2BAVPR1BHRH3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 ITGB3 2302/4885ITGA2B 1380/4885AVPR1B 4862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.